You are here
Clinical reviews and guidelines
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis
Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.EBioMedicine. 2015 May 12;2(7):671-680. eCollection 2015 Jul.
Risk of subsequent melanoma after melanoma in situ and invasive melanoma: A population-based study from 1973 to 2011
Hyemin Pomerantz, MD, David Huang, MS, Martin A. Weinstock, MD, PhDJournal of the American Academy of Dermatology, Volume 72, Issue 5, May 2015, Pages 794-800
Editors’ comment: Dr. Paolo Ascierto
In this cohort study was compared the risk for developing a new melanoma in patients with a diagnosis of melanoma in situ compared to patients with invasive melanoma. The analysis showed that patients with melanoma in situ have a higher risk of developing a new melanoma at any stage after two years from the first diagnosis as well as to develop a new invasive melanoma after 10 years from the first diagnosis of melanoma. The reasons for this phenomenon are not known, however, these results confirm the need for a follow up visit with prolonged dermatological annual even for patients with a diagnosis of melanoma in situ
443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011
Ines B. Brecht, Claus Garbe, Olaf Gefeller, Annette Pfahlberg, Jürgen Bauer, Thomas K. Eigentler, Sonja Offenmueller, Dominik T. Schneider, Ulrike LeiterEuropean Journal of Cancer, Volume 51, Issue 7, May 2015, Pages 861-868
Editors’ comment: Dr. Paolo Ascierto
Melanoma is extremely rare in children; for this reason, little is known about biology and clinical behavior of pediatric malignant melanoma. This is an interesting prospective analysis performed on 443 pediatric patients with melanoma registered in the German Central Malignant Melanoma Registry between 1983 and 2011 in order to evaluate the characteristics of the disease and prognosis. The analysis don’t show significant differences neither regarding diagnostic methods or the prognosis nor the therapeutic approach of pediatric melanoma, suggesting that should be used in children the same clinical approach used for adults.
Shenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, et al.Article in Press Abstract Purpose To investigate the association between blood levels of C-reactive protein (CRP) in patients with melanoma...
American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7731 Patients : The 2013 Zimmerman Lecture
Carol L. Shields, MD, , Swathi Kaliki, MD, Minoru Furuta, MD, Enzo Fulco, MD, Carolina Alarcon, MD, Jerry A. Shields, MDArticle in Press Purpose To analyze the clinical features and prognosis of posterior uveal melanoma based on the American Joint...
NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Helen Tucker, Nwamaka Umeweni, Janet Robertson, Jane AdamThe Lancet Oncology, Early Online Publication, 22 October 2014
No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
Maria Romina Girotti, Grazia Saturno, Paul Lorigan, Richard MaraisReview Article Molecular Oncology, In Press, Uncorrected Proof, Available online 15 August 2014
This is a review which comprehensively covers the enormous progress made in recent years in the treatment of metastatic melanoma. Starting from the explanation of the biological mechanisms which underlie them, the authors clearly illustrate the basis in the development of the various target therapies, in particular BRAF and MEK inhibitors, and the different immunotherapeutic drugs, first of all the anti-CTLA-4 ipilimumab, followed by anti-PD-1 and anti-PD-L1, not forgetting to emphasize the importance of combination therapy, which are currently the main hope for further future progress.
Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature
Giuseppe Lombardi, Anna Luisa Di Stefano, Patrizia Farina, Vittorina Zagonel, Emeline Tabouret
Cancer Treatment Reviews
Joselin D. Tacastacas, Julie Bray, Yoon K. Cohen, Joshua Arbesman, Julian Kim, Henry B. Koon, Kord Honda, Kevin D. Cooper, Meg R. GerstenblithJournal of the American Academy of Dermatology, Available online 6 May 2014
This is a comprehensive review that provides a broad overview on the mucosal melanoma, starting with the pathologic characterization, the complexity of the surgical and medical up to new targeted therapies that are currently the subject of extensive research.